Like you, we’re Kiwis thinking about health, and we’re working alongside you to improve the health of all New Zealander’s through our innovative product portfolio.
We’re taking Maxigesic® to the world, and there is still much more to come in New Zealand. Last year, Maxigesic® IV was registered in New Zealand, and this unique new combination of paracetamol and ibuprofen will provide you with an effective post-operative pain management solution for your patients that avoids the use of opioids.
Let’s talk more at NZSA 2020 about how we can turn this and other innovative thinking into actions that help improve patient outcomes in your practice.
For enquiries contact Michael Sargent